Welcome to our dedicated page for ROCHE HOLDING S/ADR news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on ROCHE HOLDING S/ADR stock.
Roche Holdings Ltd. S/ADR (RHHBY) is a leading biotechnology company with a global presence in the field of in-vitro diagnostics. Roche focuses on scientific excellence to develop medicines and diagnostics for improving and saving lives. The company's pivotal role in personalized healthcare is reflected in its commitment to transforming healthcare delivery. Roche's innovative approach encompasses the discovery and development of cutting-edge treatments, including the first CD20xCD3 bispecific antibody, Columvi® (glofitamab), for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company's recently FDA-cleared whole-slide imaging system, VENTANA DP 200, signifies Roche's dedication to revolutionizing pathology workflows through digitalization and artificial intelligence-based tools, ensuring pathologists can provide accurate and timely diagnoses. Roche's extensive portfolio and pipeline of haematology medicines demonstrate its unwavering commitment to advancing treatment options for patients worldwide.
Rhea-AI Summary
Roche (ROTKREUZ) announces healthcare professionals' excellent ratings for navify Tumor Board, POC Operations, and Lab Operations in an independent report by KLAS® Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
-
Rhea-AI Summary
Roche (RO, ROG; RHHBY) ranks third among the most sustainable healthcare companies in the Dow Jones Sustainability Indices. This marks the 15th year of Roche's leading ranking, emphasizing its commitment to sustainability in innovation management, access to healthcare, greenhouse gas emissions, water management, resource efficiency, circularity, labour practice indicators, and human rights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
-
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) presented new data from its CD20xCD3 T-cell engaging bispecific antibody programme at the 65th ASH Annual Meeting, showing durable responses in heavily pre-treated lymphoma patients. Longer-term follow-ups of Columvi and Lunsumio studies demonstrated sustained remissions, reinforcing the potential of combination regimens in earlier treatment settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
Rhea-AI Summary
Genentech, a member of the Roche Group (RO, ROG; RHHBY), presented new data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition, showcasing the durable responses in heavily pre-treated lymphoma patients with their CD20xCD3 T-cell engaging bispecific antibody program, Columvi and Lunsumio. The data also reinforced the potential of combination regimens in earlier treatment settings, supporting ongoing Phase III studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
-
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the positive results of the Phase III HAVEN 7 study at the ASH 2023, reinforcing the efficacy and safety of Hemlibra in infants with severe haemophilia A without factor VIII inhibitors. The study showed meaningful bleed control in babies up to 12 months of age, with no spontaneous bleeds requiring treatment and no new safety signals observed. Hemlibra was well tolerated and exhibited consistent safety results. The study reflects Roche's commitment to advancing treatment standards for haemophilia A patients, providing additional confidence in the efficacy and safety profile of Hemlibra for babies with severe haemophilia A.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Genentech, a member of the Roche Group (RO, ROG; RHHBY), announced the Phase III HAVEN 7 study results at ASH 2023, reinforcing the efficacy and safety of Hemlibra in infants with severe hemophilia A without factor VIII inhibitors. The study showed meaningful bleed control in babies up to 12 months of age and was well tolerated, with no new safety signals. Hemlibra provides a flexible and subcutaneous treatment option for babies, improving long-term outcomes and reducing the risk of intracranial hemorrhage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Roche (RO, ROG, RHHBY) presented positive results from the Phase III INAVO120 study, showing inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone for people with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The inavolisib combination reduced the risk of disease worsening or death by 57% and showed clinically meaningful increases in objective response rate, duration of response, and clinical benefit rate. Overall survival data were immature, but a clear positive trend was observed. The inavolisib combination was well tolerated, with no new safety signals observed. Inavolisib is currently being investigated in three Phase III clinical studies in people with PIK3CA-mutated locally advanced or metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
-
Rhea-AI Summary
Genentech (RO, ROG, RHHBY) releases positive long-term follow-up data from the pivotal, Phase III KATHERINE study in people with HER2-positive early-stage breast cancer. Kadcyla shows a statistically significant and clinically meaningful improvement in overall survival and maintains the previously reported invasive disease-free survival benefit. The safety profile of Kadcyla was consistent with previous findings and no new safety signals were identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
-
Rhea-AI Summary
Roche (RO, ROG; RHHBY) announced positive results from the Phase III INAVO120 study of inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer, showing a significant improvement in progression-free survival compared to palbociclib and fulvestrant alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
Rhea-AI Summary
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to acquire Carmot Therapeutics in a definitive merger agreement, paying a purchase price of USD 2.7 billion upfront and additional milestone payments of up to USD 400 million. Carmot's R&D portfolio includes clinical stage incretins with best-in-class potential to treat obesity, diabetes, and other diseases. The lead asset CT-388 is a Phase-2 ready dual GLP-1/GIP agonist, with potential for treating obesity and its comorbidities. The acquisition gives Roche access to a differentiated portfolio of incretins, including CT-388, CT-996, and CT-868, offering opportunities for combination therapies and expansion to other indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
FAQ
What is the current stock price of ROCHE HOLDING S/ADR (RHHBY)?
The current stock price of ROCHE HOLDING S/ADR (RHHBY) is $35.44 as of November 22, 2024.
What is the market cap of ROCHE HOLDING S/ADR (RHHBY)?
The market cap of ROCHE HOLDING S/ADR (RHHBY) is approximately 230.4B.
What is Roche Holdings Ltd. S/ADR (RHHBY) known for?
Roche is a global leader in biotechnology, specializing in in-vitro diagnostics and the development of cutting-edge medicines.
What is the significance of Columvi® (glofitamab) in Roche's portfolio?
Columvi® (glofitamab) is the first CD20xCD3 bispecific antibody that has shown promising results in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
How does Roche contribute to personalized healthcare?
Roche aims to transform healthcare delivery by focusing on scientific excellence, data insights, and partnerships with stakeholders to provide tailored treatment options for patients.
What recent innovation has Roche introduced in digital pathology?
Roche's VENTANA DP 200 whole-slide imaging system, with FDA clearance, allows pathologists to review and interpret digital pathology images efficiently, facilitating remote diagnosis and collaboration.
What is Roche's approach to advancing haematology treatments?
Roche has a robust portfolio and pipeline of haematology medicines, including T-cell engaging bispecific antibodies like Columvi®, to address the diverse needs of patients with blood cancers.
ROCHE HOLDING LTD S/ADR